Keyword: Stivarga

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

China, which has been waving through cancer drugs made by multinational pharmas, can now count a homegrown one among its approvals.

Bayer is taking a giant colon on tour. Yes, you read that right.

A strong euro doesn't explain away Bayer's consumer health stall—or the low turnout for key cancer meds Xofigo and Stivarga.

After Lilly’s Cyramza flopped a liver cancer trial in 2014, the company designed a trial for a specific subpopulation. Now, it’s back with a win.

Kidney cancer isn’t the only disease area where Merck’s Keytruda is moving in to challenge Bristol-Myers Squibb’s Opdivo.

Bayer is working to position Stivarga as part of a liver cancer treatment regimen, But that’s not going to work in England. At least, not yet.

Since NICE took the reins of England’s Cancer Drugs Fund last year, several drugmakers have seen their meds get the boot. Not Bayer.

With its latest FDA nod, Bristol-Myers Squibb’s Opdivo won the right to take on Bayer's Stivaga in liver cancer.